Sarepta Therapeutics Announces Executive and Director Changes
Ticker: SRPT · Form: 8-K · Filed: Aug 13, 2025 · CIK: 873303
| Field | Detail |
|---|---|
| Company | Sarepta Therapeutics, Inc. (SRPT) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $576,700, $400 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, governance
Related Tickers: SRPT
TL;DR
Sarepta's board and exec team got a refresh, with new directors and officers appointed.
AI Summary
On August 12, 2025, Sarepta Therapeutics, Inc. announced changes in its executive and director roles. The company elected new directors and appointed new officers, alongside adjustments to compensatory arrangements for certain executives. These changes are effective as of August 12, 2025.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Leadership changes and adjustments to compensation can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-14895 (company_id) — Commission File Number
- 93-0797222 (ein) — IRS Employer Identification No.
- 215 First Street, Cambridge, Massachus (address) — Business Address
FAQ
What specific roles were affected by the director and officer changes?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' and 'Compensatory Arrangements of Certain Officers,' but does not specify the exact roles affected in this summary.
When were these changes effective?
The changes were effective as of August 12, 2025.
Are there any details on the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not provided in this summary.
What is Sarepta Therapeutics, Inc.'s primary business?
Sarepta Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
What is the company's filing history with the SEC regarding this report?
This is a Form 8-K filed on August 13, 2025, reporting events as of August 12, 2025, with 12 public document counts.
Filing Stats: 614 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-08-13 16:10:35
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT Nasdaq Glo
- $576,700 — rif severance in the lump sum amount of $576,700 as well as a consulting fee of $400 per
- $400 — $576,700 as well as a consulting fee of $400 per hour for the consulting services pr
Filing Documents
- d59666d8k.htm (8-K) — 23KB
- 0001193125-25-179819.txt ( ) — 131KB
- srpt-20250812.xsd (EX-101.SCH) — 3KB
- srpt-20250812_lab.xml (EX-101.LAB) — 17KB
- srpt-20250812_pre.xml (EX-101.PRE) — 11KB
- d59666d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: August 13, 2025 By: /s/ Douglas S. Ingram Douglas S. Ingram Chief Executive Officer